Development research of new therapies targeting VEGF receptor that was expressed in oral cancer cells, and its signaling

• Project/Area Number: 24593033
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Surgical dentistry
• Research Institution: Hiroshima University
• Principal Investigator: KOIZUMI Koichi 広島大学, 医歯薬保健学研究院, 助教 (30335682)
• Co-Investigator(Kenkyū-buntansha): YOSHIOKA Yukio 広島大学, 大学院医歯薬保健学研究院, 助教 (20335665) ; HAYASHIDO Yasutaka 広島大学, 病院, 講師 (70243251) ; OKAMOTO Tetuji 広島大学, 大学院医歯薬保健学研究院, 教授 (00169153)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Project Status: Completed (Fiscal Year 2014)
• Budget Amount: ¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000); Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000); Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2012: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
• Keywords: VEGF / 口腔癌 / 分子標的治療薬 / オートクライン機構 / PI3-Akt系 / 分子標的治療

Outline of Final Research Achievements

It is known that vascular endothelial growth factor (VEGF) is produced by tumor cells,and control the tumor growth, invasion and metastasis through a paracrine mechanism.
In this study, we revealed that tumor cells express VEGF receptors, and the possibility of its motility and proliferation ability is controlled by autocrine mechanism via the VEGF receptor / PI3 / Akt system. We are currently studying the development of new therapies targeting the VEGF receptor system.